Moderna and Merck Shares Fall After Possible Melanoma Data Leak
· Business · Bloomberg, MarketWatch, Forbes
Moderna and Merck shares declined following a potential data leak concerning a clinical melanoma study. The incident involves unauthorized disclosure of trial information related to their collaborative skin cancer treatment. Investors responded with caution as the implications of the security breach are evaluated. The companies have not yet released detailed statements regarding the extent of the compromised information. Further updates from regulatory authorities and the pharmaceutical firms are expected as the investigation continues.
Why it matters
The incident directly impacts investors and stakeholders in Moderna and Merck, highlighting potential vulnerabilities in clinical trial data security for major biotechnology firms.
Read the original report — Bloomberg
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.